A therapeutic galcanezumab, initially known as LY2951742, represents the critical advance in migraine management. Its chemical structure is that of a humanized monoclonal antibody, specifically targeting the target. https://ztndz.com/story28727550/galcanezumab-a-deep-dive-into-ly2951742-and-its-chemical-identity